drugset / Trial / NCT04723186
MT1002 Phase II Study in ACS Patients With PCI
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI. Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve target ACT.
Timeline
- Start
- 2020-12-02
- Primary completion
- 2023-08-31
- Completion
- 2023-08-31
Outcome
Outcome not reported
Stopped: “The study was decided to be terminated due to commercial considerations,（not the safety issues of the product）.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT1002 | Peptide | 1.2 mg/kg | Intravenous |
| Subject | MT1002 | Peptide | 1.8 mg/kg | Intravenous |
| Subject | MT1002 | Peptide | 2.3 mg/kg | Intravenous |